On August 30, 2023, representatives of JSC “National Holding QazBioPharm” met with representatives of Sinopharm in the People’s Republic of China. Following the negotiations, the parties reached the following agreements:

To explore the possibility of localizing the production of pharmaceutical products from the Sinopharm and Sinocell portfolios at Kazakhstani manufacturing facilities, with the Unified Distributor assisting in identifying a local partner.

To study the possibility of signing a memorandum of cooperation between the Ministry of Health of the Republic of Kazakhstan and Sinopharm regarding:

Localization of innovative pharmaceutical production within Kazakhstan;

Provision of integrated solutions to enhance the efficiency of healthcare professionals and optimize the management of medical organizations;

Exchange of experience and provision of scientific and educational grants for Kazakhstani researchers and pharmacy students, among other initiatives.

China National Pharmaceutical Group, or Sinopharm, is the largest Chinese pharmaceutical corporation and one of the world’s leading companies. Founded in 1998, its headquarters are in Beijing, and the controlling stake of Sinopharm is held by SASAC (State-owned Assets Supervision and Administration Commission).

Sinopharm is the sixth-largest vaccine manufacturer in the world and supplies 80% of vaccines for China’s immunization program. The Group includes over 1,500 subsidiaries and branches, as well as six publicly listed companies engaged in research, production, logistics, and distribution of pharmaceuticals and traditional medicine products (including anesthetics, antibiotics, psychotropic, antitumor, anti-infective, cardiovascular, and respiratory drugs), medical equipment production and service (X-ray machines, test kits), financial services, international supply, organization of exhibitions and conferences, as well as management of warehouse and pharmacy networks. Through its logistics centers, Sinopharm serves over 230,000 corporate clients.

Sinopharm was established in 1998 through the merger of state pharmaceutical and medical assets — China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade, and China National Medical Device. In 2009, China National Biotec Group also became part of the Group.

In 2020, China National Pharmaceutical Group and its subsidiaries (China National Biotec Group and Wuhan Institute of Biological Products Co.) became one of the leading centers for the development of the COVID-19 vaccine.

On May 8, 2021, the COVID-19 vaccine produced by Sinopharm received WHO approval, becoming the first WHO-approved COVID-19 vaccine manufactured outside the European Union. In September 2021, Sinopharm agreed to establish a manufacturing facility for the Chinese COVID-19 vaccine in Hungary.

China National Pharmaceutical Group is engaged in the distribution and logistics of medical goods (through Sinopharm Group), retail sales of pharmaceuticals (through Guoda and other pharmacy chains), development of biological products (through six biological product institutes), pharmaceutical R&D (through Sinopharm United Engineering Corporation), pharmaceutical production (through China National Pharmaceutical Industry), chemical reagents production (through Sinopharm Chemical Reagent Co.), production of traditional Chinese medicine (through China National Corporation of Traditional and Herbal Medicine), medical equipment production (through China National Scientific Instruments and Materials Corporation and China National Medical Equipment Industry Corporation), export and import of medical goods (through China National Pharmaceutical Foreign Trade Corporation), and organization of medical exhibitions and conferences (through Reed Sinopharm Exhibition).